子宫内膜癌辅助放化疗后中性粒细胞减少影响因素分析的回顾性研究
该回顾性研究分析了2012年1月至2023年6月在山东第一医科大学第一附属医院妇科肿瘤科接受辅助放化疗的子宫内膜癌患者,共144例符合纳入标准,接受330个周期辅助化疗,其中96例(66.7%)发生中性粒细胞减少,共发生140次。单因素GEE分析显示放化疗前白细胞、中性粒细胞绝对计数、单核细胞绝对计数、血尿素氮及铂类/多西他赛方案与中性粒细胞减少相关,多因素GEE分析显示放化疗前中性粒细胞绝对计数、单核细胞绝对计数及铂类/多西他赛方案为独立影响因素,多因素Logistic回归显示首个化疗周期即加入放疗为独立影响因素。
要点
- 144例子宫内膜癌患者接受330个周期辅助化疗,96例(66.7%)发生中性粒细胞减少,共140次。
- 多因素GEE分析显示放化疗前中性粒细胞绝对计数(OR=0.552)和单核细胞绝对计数(OR=0.047)及铂类/多西他赛方案(OR=2.437)为中性粒细胞减少的独立影响因素。
- 多因素Logistic回归显示首个化疗周期即加入放疗(OR=4.413)为中性粒细胞减少的独立影响因素。
核心结论
- 放化疗前中性粒细胞绝对计数和单核细胞绝对计数低、采用铂类/多西他赛方案的患者在每个放化疗周期需密切监测。
- 首个化疗周期应避免同期加入放疗。
研究设计与样本
- 回顾性研究,纳入2012年1月至2023年6月山东第一医科大学第一附属医院妇科肿瘤科接受辅助放化疗的子宫内膜癌患者,共144例符合纳入标准,接受330个周期辅助化疗。
- 中性粒细胞减少定义为外周血中性粒细胞绝对计数低于2×10^9/L。
- 采用广义估计方程(GEE)分析影响因素,并采用Logistic回归进一步分析不同化疗周期加入放疗对中性粒细胞减少的影响。
主要发现
- 144例患者中96例(66.7%)发生中性粒细胞减少,共发生140次。
- 单因素GEE分析显示放化疗前白细胞(OR=0.827;95%CI,0.701-0.976)、中性粒细胞绝对计数(OR=0.749;95%CI,0.586-0.957)、单核细胞绝对计数(OR=0.047;95%CI,0.008-0.283)、血尿素氮(OR=0.857;95%CI,0.741-0.991)、铂类/多西他赛方案(OR=2.284;95%CI,1.130-4.618)与中性粒细胞减少相关(p<0.05)。
- 多因素GEE分析显示放化疗前中性粒细胞绝对计数(OR=0.552;95%CI,0.973-2.231)、单核细胞绝对计数(OR=0.047;95%CI,0.004-0.052)、铂类/多西他赛方案(OR=2.437;95%CI,1.087-5.464)为中性粒细胞减少的独立影响因素(p<0.05)。
- 多因素Logistic回归显示首个化疗周期即加入放疗(OR=4.413;95%CI,1.238-18.891)为中性粒细胞减少的独立影响因素(p<0.05)。
临床怎么用
- 作者认为,放化疗前中性粒细胞绝对计数和单核细胞绝对计数低、采用铂类/多西他赛方案的患者在每个放化疗周期需密切监测。
- 作者认为,首个化疗周期应避免同期加入放疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This retrospective study aimed to investigate the factors influencing the occurrence of neutropenia in patients with endometrial cancer (EC) following adjuvant chemoradiotherapy (CRT). METHODS: Retrospective analysis of EC patients who underwent adjuvant CRT from January 2012 to June 2023 in the Department of Gynecology and Oncology of the First Affiliated Hospital of Shandong First Medical University. Neutropenia was defined as an Absolute Neutrophil Count (ANC) of peripheral blood neutrophils below 2 × 109/L. Factors affecting neutropenia in EC patients treated with CRT using Generalized Estimating Equation (GEE), and Logistic regression was used to further analyze the effect of adding radiotherapy to different chemotherapy cycles on neutropenia, so that patients receive optimal adjuvant CRT while the risk of neutropenia is appropriately controlled. RESULTS: A total of 144 patients met the inclusion criteria. They underwent 330 cycles of adjuvant chemotherapy, of whom 96 (66.7%) developed neutropenia, which occurred 140 times. The results of one-way GEE analysis showed that before CRT, White Blood Cell (WBC) (OR = 0.827; 95%CI, 0.701-0.976), ANC (OR = 0.749; 95%CI, 0.586-0.957), Absolute Monocyte Count (AMC) (OR = 0.047; 95%CI, 0.008-0.283), Blood Urea Nitrogen (BUN) (OR = 0.857; 95%CI, 0.741-0.991), platinum and docetaxel (platinum/docetaxel) dosing regimen (OR = 2.284; 95%CI, 1.130-4.618) were associated with neutropenia with adjuvant CRT for EC (p < 0.05), results of multifactorial GEE analysis showed that before adjuvant CRT ANC (OR = 0.552; 95%CI, 0.973-2.231), AMC (OR = 0.047; 95%CI, 0.004-0.052), platinum/docetaxel (OR = 2.437; 95%CI, 1.087-5.464) were an independent influence on neutropenia in adjuvant CRT for EC (p < 0.05). Multifactorial Logistic regression shows addition of radiotherapy to the first cycle of chemotherapy (OR = 4.413; 95%CI, 1.238-18.891) was an independent influence of neutropenia (p < 0.05). CONCLUSIONS: Patients with low pre-CRT ANC and AMC, platinum/docetaxel dosing regimens need to be closely monitored during each cycle of CRT. Also, the concurrent addition of radiotherapy should be avoided during the first cycle of chemotherapy.
引用
- Fan M, Zhang W, Zhou Y, et al. A retrospective study on the analysis of influencing factors of neutropenia in endometrial cancer with adjuvant chemoradiotherapy. Radiat Oncol. 2024. PMID: 38890652. doi:10.1186/s13014-024-02469-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。